Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.

Marco StellatoGiuseppe ProcopioUgo De GiorgiMarco MaruzzoDavide BimbattiAlessia MennittoAndrea SbranaGiandomenico RovielloChiara CasadeiPierangela SepeSandro PignataDaniele Santini

Published in: Journal of translational medicine (2021)

ICIs seem to maintain efficacy even after early interruption due to severe irAE.

Keyphrases

study protocol
clinical trial
early onset
randomized controlled trial
open label